三胶补血膏治疗晚期非小细胞肺癌化疗相关性贫血临床观察

Clinical Observation on Treatment of Chemotherapy Related Anemia in Advanced Non-Small Cell Lung Cancer with Sanjiao Buxue Ointment(三胶补血膏)

目的 观察三胶补血膏治疗晚期非小细胞肺癌化疗相关性贫血的临床疗效。方法 研究采用前瞻、随机、单盲、对照研究,共纳入75例患者,随机分为三组,三胶组予三胶补血膏治疗,人促红细胞生成素(EPO)组予治疗,联合组予三胶补血膏联合EPO治疗,21 d为1个疗程,共观察3个疗程,观察血液学指标(红细胞、血红蛋白、红细胞压积)、中医证候积分、KPS评分。结果 最终完成71例,3组治疗前后红细胞、血红蛋白、红细胞压积、中医症候积分、KPS评分均差异有统计学(P=0.006 7;P=0.025 8;P=0.003 1;P<0.05;P=0.039),治疗后三组组内、组间比较以上观察指标均差异有统计学(P<0.05),以EPO组为对照组,三胶组与EPO组比较,联合组与EPO组比较,红细胞、血红蛋白、红细胞压积、中医症候积分、KPS评分均差异有统计学(P<0.05)。3组均未见严重的不良反应,EPO组有1例血栓事件,其他两组均未见不良反应。结论 三胶补血膏治疗非小细胞肺癌化疗相关性贫血临床疗效可靠,还可以改善中医证候及生活质量,临床可作为EPO的补充治疗手段,值得进一步临床推广。

Objective To observe the clinical efficacy of Sanjiao Buxue Ointment(三胶补血膏)in the treatment of chemother-apy-related anemia in advanced non-small cell lung cancer.Methods In this study,a prospective,randomized,single-blind and controlled study was adopted.A total of 75 patients were included and randomly divided into three groups.Sanjiao Buxue Ointment group was given Sanjiao Buxue Ointment.Erythropoietin(EPO)group was given the EPO.The combination group was given Sanjiao Buxue Ointment and EPO.Twenty-one days was a course of treatment,a total of 3 courses of treatment were ob-served,and hematological indicators(red blood cells,hemoglobin,hematocrit),TCM syndrome scores and Karnofsky(KPS)scores were observed.Results Seventy-one cases were finally completed,and there were statistical differences in red blood cells,hemo-globin,hematocrit,TCM syndrome scores and KPS scores before and after treatment in the three groups(P=0.0067;P=0.0258;P=0.0031;P<0.05;P=0.039).There were statistical differences(P<0.05)in the above indexes among the three groups after treatment(P<0.05).Taking the EPO group as the control group,there were statistical differences in hemoglobin,hemato-crit,TCM symptom scores and KPS scores between the Sanjiao Buxue Ointment group and the EPO group,and between the combi-nation group and the EPO group(P<0.05).No serious adverse reactions were seen in the three groups,and there was 1 throm-botic event in the EPO group,and no adverse reactions were seen in the other two groups.Conclusion Sanjiao Buxue Ointment has a reliable clinical curative effect in the treatment of non-small cell lung cancer chemotherapy-related anemia,and can also improve TCM syndromes and quality of life.It can be used as a supplementary treatment for EPO in clinical practice,and it is worthy of further clinical promotion.